SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as the community eagerly anticipates potential European Commission approval for its ANKTIVA cancer immunotherapy, alongside significant developments from the USA-Saudi Biotech Alliance that could broaden its global reach for multiple cancer indications and ignite a substantial short squeeze.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as the community eagerly anticipates topline results from its Phase 3 superiority trial of Axpaxli for wet AMD, which the company announced will be released Tuesday. Sentiment is overwhelmingly bullish that the early data release and plans for presentation at a major retina conference signal strong positive outcomes, alongside persistent rumors of a sweetened takeover bid from Sanofi.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending following its announcement of preliminary Q4 results that exceeded all guided metrics, fueling optimism about its strong subscription revenue growth and critical position in AI-driven data security. The community is actively debating its valuation and competitive moat amid broader software sector volatility, with many calling it a compelling buy despite recent market pressures.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending after Hapag-Lloyd announced a definitive agreement to acquire the company for $35 per share in cash, triggering intense community discussion over the offer's valuation, potential for a short squeeze, and the impact of Israeli government approval on the deal's expected 2026 completion.

Corsair Gaming, Inc. designs and supplies hardware components for personal computers. It operates through the Gamer and Creator Peripherals, and Gaming Components and Systems segments. The Gamer and Creator Peripherals segment offers gaming keyboards, mice, headsets, controllers, and gaming gear including capture cards, Stream Decks, USB microphones, studio accessories, and EpocCam software, as well as coaching and training services. The Gaming Components and Systems segment focuses on creating power supply units, or PSUs, cooling solutions, computer cases, DRAM modules, prebuilt, and custom-built gaming PCs. The company was founded by Andrew J. Paul in 1994 and is headquartered in Milpitas, CA.

Corsair Gaming Inc

Corsair Gaming is experiencing a significant surge following its strong Q4 earnings report and the announcement of a $50 million share repurchase program. The community is actively discussing its perceived undervaluation, high short interest, and potential to capitalize on AI-driven hardware demand, leading to widespread speculation of a short squeeze.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoin (BTC) is trending amid sharp price declines below critical support levels, sparking intense debate among retail traders about its immediate future and prompting fears of a deeper crash. However, this volatility is viewed by some institutional investors as a "flush out" and a buying opportunity, especially as new legislative initiatives, such as Truth Social's ETF filing and the CLARITY Act, suggest increasing mainstream integration.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Churchill Capital Corp X 

The stock is surging on high anticipation for its upcoming NYSE debut as Infleqtion (INFQ) following a merger that saw near-zero shareholder redemptions, signaling robust investor confidence and a strong capital position; the community is highly bullish on its leading quantum technology, including a recent NASA contract, viewing it as significantly undervalued compared to sector peers.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid a heated debate surrounding a critical short report alleging certification delays and technical shortcomings, while bullish investors highlight significant institutional investment from BlackRock and strategic partnerships with companies like NVIDIA and Stellantis, as the pre-revenue eVTOL sector navigates regulatory milestones.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is generating high community engagement and volatility following its recent convertible notes offering, as investors debate whether the capital raise is strategic for accelerating global deployment and new initiatives, or a sign of dilution. Bulls emphasize the company's unique direct-to-device technology, institutional accumulation, and potential in AI and government sectors, while others remain cautious regarding satellite launch timelines and valuation.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is trending following a strong Q4 earnings beat and significantly raised 2026 guidance, fueled by robust AI data center demand. Despite this positive news, the stock experienced a notable dip, sparking community debate about market overreaction and driving "buy the dip" sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNexus Gene Lab Corp. (BGLC) announced on Wednesday that it has entered into definitive agreements with Asia-based firms Fidelion Diagnostics Pte. and Tongshu Biotechnology, among other parties, to commercialize VitaGuard in Southeast Asia.VitaGuard is a high-fidelity, tumor-naïve liquid biopsy platform for minimal residual disease, meaning it detects tiny fragments of tumor DNA without requiring a tumor tissue sample. Minimal residual disease (MRD) is a small number of cancer cells that remain in the body during or after treatment, which are undetectable by standard methods.<h2 class="st-heading-2">Transaction Terms And Details</h2>China-headquartered Tongshu Gene is the original developer of the VitaGuard technology. The firm serves as the research and development, as well as manufacturing partner of Singapore-based Fidelion.The partnership <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/12/3186213/0/en/BioNexus-Gene-Lab-Corp-Nasdaq-BGLC-Announces-Strategic-Agreements-with-Fidelion-Diagnostics-for-Southeast-Asia-MRD-Commercialization.html">aims</a> to support the planned commercialization of MRD testing in Southeast Asia with an initial focus in Singapore and Malaysia.Under the agreement, BGLC will receive new Fidelion shares equal to at least 15 % of Fidelion’s fully diluted share capital, and Fidelion will receive newly issued, restricted BGLC shares equal to 19.9% of BGLC’s pre-money outstanding shares. The BGLC share issuance will be made in a private transaction, the company said.The completion of the transaction is conditioned upon an Intellectual Property License Agreement granting BGLC exclusive commercialization rights across the Association of Southeast Asian Nations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BGLC">BGLC stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘extremely low’ to ‘extremely high’ levels.BGLC stock is up 68% this year and approximately 42% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-commits-up-to-10-billion-additional-investment-in-us-over-five-years/cLPI6vHREdJ">Toyota Commits Up To $10B Additional Investments In US Over Five Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention?

The partnership aims to support the planned commercialization of minimal residual disease testing in Southeast Asia.

Equity

The partnership aims to support the planned commercialization of minimal residual disease testing in Southeast Asia.


BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

BGLC
BioNexus Gene Lab Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BGLC News

BGLCBioNexus Gene Lab Corp